Aytu Biopharma Inc (AYTU) FinancialsAYTUAytu Biopharma Inc

Aytu Biopharma Inc (AYTU) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ADHD portfolio, accounting for 94.7% of total sales, equivalent to $13.16M. Other significant revenue streams include Pediatric portfolio and Other . Understanding this composition is critical for investors evaluating how AYTU navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Aytu Biopharma Inc maintains a gross margin of 55.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -32.75%, while the net margin is -45.27%. These profitability ratios, combined with a Return on Equity (ROE) of -97.42%, provide a clear picture of how effectively AYTU converts its operational activities into shareholder value.

In the context of the broader market, AYTU competes directly with industry leaders such as CLRB and UPC. With a market capitalization of $25.55M, it holds a significant position in the sector. When comparing efficiency, AYTU's gross margin of 55.10% stands against CLRB's N/A and UPC's 34.57%. Such benchmarking helps identify whether Aytu Biopharma Inc is trading at a premium or discount relative to its financial performance.

Aytu Biopharma has faced declining revenues, with Q3 2026 net revenue at $12.4 million, down from $18.5 million year-over-year. The gross margin has also decreased to 55.10%, reflecting increasing costs and competitive pressures.